Plain-English translation of NCT05242159 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a specific immune marker called anti-annexin A2 antibodies in people hospitalized with COVID-19. When your body fights the coronavirus, it sometimes produces antibodies that may accidentally attack your own cells. This study wants to understand whether these particular antibodies are present in COVID-19 patients and whether they're connected to serious complications like lung damage or dangerous blood clots.
COVID-19 can trigger your immune system to overreact and create antibodies that harm your own body. Doctors need to understand which immune markers signal that a patient is at risk for severe complications like blood clots or lung injury, so they can better predict who needs closer monitoring and more aggressive treatment.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will donate a blood sample while you are in the hospital being treated for COVID-19. The sample will be tested to look for the specific antibodies researchers are studying. This is a one-time or minimal-visit study focused on understanding your immune response to the virus, not testing a new medication or treatment.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
France
~300 participants
Started
May 2021
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Valéry Salle, MD
Centre Hospitalier Universitaire, Amiens
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.